ArticleIndian dermatology online journal
Efficacy and Safety of Cysteamine in Melasma in Patients of Skin of Colour: A Brief Report.
Article in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melasma is a common disorder of pigmentation. Traditional treatments often come with limitations, prompting the need for alternative newer therapies. Cysteamine cream, a new topical depigmenting drug, has shown potential in treating melasma while maintaining a good safety profile. Aim: This case series aims to evaluate the efficacy and safety of cysteamine cream in treating melasma in patients of skin of colour (Fitzpatrick's skin types III, IV, and V). Patients and Methods: Ten Indian women with Fitzpatrick skin types III-V with epidermal melasma diagnosed clinically and by Wood's lamp examination, with history of no other medications other than sunscreen use in the last 4 weeks, applied cysteamine cream (5% cysteamine hydrochloride) once daily for 15 minutes, followed by rinsing with water, over 6 weeks. Broad-spectrum sunscreen with SPF 30+ was used during the day. The primary outcomes were the modified Melasma Area and Severity Index (mMASI) score and patients' satisfaction score. Results: All patients showed a significant reduction in mMASI scores, with an average improvement of 29.72%. High patient satisfaction (44.6%) was reported, and adverse effects reported in minority (20%) were minimal, including transient mild stinging and lightening of surrounding skin. Limitations: Small sample size, lack of a control group, and no long-term follow-up. Conclusion: Cysteamine cream is an effective and safe treatment for melasma in women of colour. This case series supports its use as a first-line therapy for melasma, offering a promising option for patients who may experience adverse effects from traditional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.